Park JS, et al. - After preoperative chemoradiotherapy (CRT), researchers investigated clinicopathologic and molecular characteristics, as well as the prognostic value of human epidermal growth factor receptor-2 (HER2)-positivity in residual mid- and/or low-rectal cancers. To assess HER2 status, surgical specimens from 145 subjects with residual rectal cancer following preoperative CRT between January 2006 and January 2011 were utilized. They found HER2 positivity in a minority of rectal cancer patients. It was noted that HER2 positivity was not significantly correlated with clinicopathologic and molecular characteristics. These results could be useful in understanding the clinicopathologic impact of HER2 status in rectal cancers.